Loading...
•
Dec 31, 2021
McKesson Q3 2022 Earnings Report
McKesson reported strong financial results driven by strategic growth initiatives and value creation.
Key Takeaways
McKesson's Q3 2022 results showed a 10% increase in total revenues to $68.6 billion and a 34% increase in adjusted earnings per diluted share to $6.15. The company raised its fiscal 2022 adjusted earnings per diluted share guidance to $23.55 to $23.95.
Total revenues increased by 10% year-over-year to $68.6 billion.
Adjusted Earnings per Diluted Share increased by 34% year-over-year to $6.15.
Fiscal 2022 Adjusted Earnings per Diluted Share guidance was raised to $23.55 to $23.95.
McKesson shipped over 370 million vaccines on behalf of the U.S. government through January 31, 2022.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson raised fiscal 2022 Adjusted Earnings per Diluted Share guidance to $23.55 to $23.95 to reflect strong operating performance and increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs.
Positive Outlook
- $1.75 to $2.15 related to the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs
- $0.75 to $0.95 related to the COVID-19 tests and impairments for personal protective equipment and related products
- $0.49 related to year-to-date gains and losses associated with McKesson Ventures’ equity investments
- Strong operating performance across all segments
- Increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs